419 related articles for article (PubMed ID: 16291771)
21. Comparative pharmacology of newer progestogens.
Kuhl H
Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
[TBL] [Abstract][Full Text] [Related]
22. The preclinical biology of a new potent and selective progestin: trimegestone.
Winneker RC; Bitran D; Zhang Z
Steroids; 2003 Nov; 68(10-13):915-20. PubMed ID: 14667983
[TBL] [Abstract][Full Text] [Related]
23. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.
Duijkers IJ; Klipping C; Grob P; Korver T
Eur J Contracept Reprod Health Care; 2010 Oct; 15(5):314-25. PubMed ID: 20695770
[TBL] [Abstract][Full Text] [Related]
24. The pharmacology of nomegestrol acetate.
Ruan X; Seeger H; Mueck AO
Maturitas; 2012 Apr; 71(4):345-53. PubMed ID: 22364709
[TBL] [Abstract][Full Text] [Related]
25. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Simoncini T; Genazzani AR
Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
[TBL] [Abstract][Full Text] [Related]
26. Preclinical and clinical properties of trimegestone: a potent and selective progestin.
Sitruk-Ware R; Bossemeyer R; Bouchard P
Gynecol Endocrinol; 2007 Jun; 23(6):310-9. PubMed ID: 17616854
[TBL] [Abstract][Full Text] [Related]
27. Why use of dienogest for the first contraceptive pill with estradiol?
Mueck AO; Seeger H; Bühling KJ
Gynecol Endocrinol; 2010 Feb; 26(2):109-13. PubMed ID: 19672744
[TBL] [Abstract][Full Text] [Related]
28. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
Rübig A
Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological, metabolic and clinical aspects of new oral contraceptive associations containing natural estrogens].
Ferrari S; Piacenti I; Napolitano A; Cagnacci A
Minerva Ginecol; 2014 Feb; 66(1):91-102. PubMed ID: 24569408
[TBL] [Abstract][Full Text] [Related]
30. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells.
Botella J; Duranti E; Viader V; Duc I; Delansorne R; Paris J
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):77-84. PubMed ID: 7577723
[TBL] [Abstract][Full Text] [Related]
31. [Disadvantages of third generation progestins].
Sitruk-ware R
Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318228
[TBL] [Abstract][Full Text] [Related]
32. Conception and pharmacodynamic profile of drospirenone.
Elger W; Beier S; Pollow K; Garfield R; Shi SQ; Hillisch A
Steroids; 2003 Nov; 68(10-13):891-905. PubMed ID: 14667981
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea.
Witjes H; Creinin MD; Sundström-Poromaa I; Martin Nguyen A; Korver T
Eur J Contracept Reprod Health Care; 2015; 20(4):296-307. PubMed ID: 25712537
[TBL] [Abstract][Full Text] [Related]
34. The pharmacology of dienogest.
Ruan X; Seeger H; Mueck AO
Maturitas; 2012 Apr; 71(4):337-44. PubMed ID: 22364708
[TBL] [Abstract][Full Text] [Related]
35. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
[TBL] [Abstract][Full Text] [Related]
36. Progestins and breast cancer.
Pasqualini JR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():32-41. PubMed ID: 17943537
[TBL] [Abstract][Full Text] [Related]
37. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits.
Sitruk-Ware R
Menopause; 2002; 9(1):6-15. PubMed ID: 11791081
[TBL] [Abstract][Full Text] [Related]
38. Classification and pharmacology of progestins.
Schindler AE; Campagnoli C; Druckmann R; Huber J; Pasqualini JR; Schweppe KW; Thijssen JH
Maturitas; 2003 Dec; 46 Suppl 1():S7-S16. PubMed ID: 14670641
[TBL] [Abstract][Full Text] [Related]
39. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.
Lundeen SG; Zhang Z; Zhu Y; Carver JM; Winneker RC
J Steroid Biochem Mol Biol; 2001 Aug; 78(2):137-43. PubMed ID: 11566438
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation.
García-Becerra R; Ordaz-Rosado D; Noé G; Chávez B; Cooney AJ; Larrea F
Reproduction; 2012 Feb; 143(2):211-9. PubMed ID: 22065861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
